Navigation Links
Optimer Pharmaceuticals Receives Production Patent for Lead Product Candidate Fidaxomicin
Date:4/13/2009

SAN DIEGO, April 13 /PRNewswire-FirstCall/ -- Optimer Pharmaceuticals, Inc. (Nasdaq: OPTR) announced today that the United States Patent and Trademark Office issued a production patent (U.S. Patent No. 7,507,564) covering steps used in the manufacture of fidaxomicin, which is currently in its second Phase 3 clinical trial for the treatment of Clostridium difficile infection, or CDI.

(Logo: http://www.newscom.com/cgi-bin/prnh/20090413LA97352LOGO)

"The issuance of this production patent is another important milestone in strengthening the patent estate of our lead product candidate, fidaxomicin," said Michael N. Chang, Ph.D., President and CEO of Optimer. "We believe this patent and the issued polymorphic Form A patent, along with additional pending patent applications, will enhance our intellectual property protection for fidaxomicin."

Fidaxomicin is the first in a new class of antibiotics called macrocyclics, which inhibit the bacterial enzyme RNA polymerase, resulting in the death of Clostridium difficile. The narrow spectrum profile of fidaxomicin may eradicate Clostridium difficile selectively with minimal disruption to the normal intestinal flora. This may facilitate the return of the normal physiological conditions in the colon and reduce the probability of CDI recurrence.

About Optimer Pharmaceuticals

Optimer Pharmaceuticals, Inc. is a biopharmaceutical company focused on discovering, developing and commercializing innovative anti-infective products to treat serious infections and address unmet medical needs. Optimer has two late-stage anti-infective product candidates under d
'/>"/>

SOURCE Optimer Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
2. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
3. Solvay Pharmaceuticals, Inc. and Wyeth Pharmaceuticals Announce Receipt of an FDA Action Letter for Bifeprunox, an Investigational Treatment for Schizophrenia
4. Callisto Pharmaceuticals Opens Additional Sites for Phase II Clinical Trial of Atiprimod in Advanced Carcinoid Cancer Patients
5. WallSt.net (www.wallst.net) Updates the Investment Community Through an All-New Interview With RegeneRx Biopharmaceuticals CEO
6. Quark Pharmaceuticals, Inc. Presented Positive Preclinical Results of Systemic RNAi Compound for Acute Renal Failure (ARF)
7. Peregrine Pharmaceuticals Doses First Patient in Cotara(R) Phase II Brain Cancer Trial In India
8. Nabi Biopharmaceuticals Announces Second Quarter 2007 Financial Results
9. Access Pharmaceuticals Provides Update on Clinical Development Plan of ProLindac
10. Quark Pharmaceuticals Extends Research Agreement with State University of New York for Proprietary siRNA Compounds for Acute Hearing Loss
11. Acura Pharmaceuticals, Inc. Secures Financing to Fund Pivotal Phase III Clinical Trial for Lead Aversion(R) Technology Product Candidate
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/19/2014)... , Dec. 19, 2014   Hospira, Inc. ... provider of injectable drugs and infusion technologies, today announced ... 33rd Annual Healthcare Conference on Wednesday, Jan. 14, 2015, ... is scheduled to begin at 10:30 a.m. Pacific time ... to all interested parties through a live audiocast accessible ...
(Date:12/19/2014)... Dec. 19, 2014  Monarch America Inc. (OTCQB: CANK) ... is pleased to provide this review of the Company,s ... 2015. "Over this past year, we achieved ... am extremely proud to say that Monarch America is ... it has ever been," stated Eric Hagen , ...
(Date:12/19/2014)... , Dec. 18, 2014 Somewhere between dropping ... health was forgotten. But Audicus , a next-generation ... better this new year. Hearing loss is ... aging population, though it is often unaddressed. Forty-eight million ... has a hearing aid, mainly due to price. Hearing ...
Breaking Medicine Technology:Monarch America Inc. CEO Reviews Recent Achievements and Provides Outlook for 2015 2Monarch America Inc. CEO Reviews Recent Achievements and Provides Outlook for 2015 3Audicus Will Help People Resolve to Hear Better in 2015 2
... , - Research Collaboration ... Jubilant Organosys Ltd, headquartered ... subsidiary,Jubilant Biosys Ltd, has signed a research,collaboration agreement ... into the international pharmaceutical company,s pre-clinical,pipeline. Under the ...
... EPSScentral LLC today announced its readiness to assist ... the face of WHO,s phase 5 classification of the ... 5 "... is a strong signal that a pandemic ... measures is short." (Logo: http://www.newscom.com/cgi-bin/prnh/20080701/DC26612LOGO ...
Cached Medicine Technology:Jubilant Enters Research Collaboration With AstraZeneca 2Jubilant Enters Research Collaboration With AstraZeneca 3Jubilant Enters Research Collaboration With AstraZeneca 4EPSScentral Responds to Pandemic Alert 2
(Date:12/20/2014)... New York, NY (PRWEB) December 20, 2014 ... ) that allege a metal-on-metal version of the ... move forward in state and federal courts, Bernstein ... in New Jersey’ Bergen County Superior Court on ... were permitted to begin deposition of plaintiffs on ...
(Date:12/20/2014)... The Doctor’s Office Urgent Care of Paramus, New Jersey has ... They’ve treated over 40,000 patients while carrying out their ... to the Paramus area. , For 2015, the practice ... of top-notch board certified physicians: Christine Milosis MD, Sandra Ugras ... doctors will work tirelessly to carry out The Doctor’s ...
(Date:12/20/2014)... The aftermath of the November 24th hack on Sony ... Hollywood, but worldwide. As reported in the Los ... attack are starting a finger-pointing game which could put some ... are not the only ones affected, regular employees who had ... times ahead, agents and lawyers could be in for some ...
(Date:12/20/2014)... (PRWEB) December 20, 2014 The Twin ... protection education event in the nation! Over 250 financial ... the minute information on the industry, get motivated to ... of real people facing and overcoming the challenges of ... all across the nation came together to attend The ...
(Date:12/19/2014)... Montrose, Colorado (PRWEB) December 20, 2014 It’s ... many, travel is something that is put to the wayside ... those who still have that travel “itch” and that burning ... Inn Montrose accommodates families on their journey to Telluride with ... trip, get visitors to and from the resort, and ensure ...
Breaking Medicine News(10 mins):Health News:New Jersey Court Overseeing DePuy Pinnacle Hip Lawsuits Issues New Order, Bernstein Liebhard LLP Reports 2Health News:New Jersey Court Overseeing DePuy Pinnacle Hip Lawsuits Issues New Order, Bernstein Liebhard LLP Reports 3Health News:New Jersey Court Overseeing DePuy Pinnacle Hip Lawsuits Issues New Order, Bernstein Liebhard LLP Reports 4Health News:The Doctor's Office Urgent Care Adds 3 New Physicians to Their Growing Medical Team 2Health News:Sony Pictures Hack Perfect Example of the Reach a Single Cyber Attack Can Have 2Health News:Sony Pictures Hack Perfect Example of the Reach a Single Cyber Attack Can Have 3Health News:Sony Pictures Hack Perfect Example of the Reach a Single Cyber Attack Can Have 4Health News:Sony Pictures Hack Perfect Example of the Reach a Single Cyber Attack Can Have 5Health News:The 13th Annual Twin Cities DI Day Now On Video 2Health News:The 13th Annual Twin Cities DI Day Now On Video 3Health News:Days Inn Montrose Colorado Delivers Last Minute Holiday Season Ski Getaway Accommodations 2
... made using unusual metals could form an effective treatment against ... immunity to other drugs, according to research at the University ... study, published in the Journal of Medicinal Chemistry , ... metals Ruthenium and Osmium, which are found in the same ...
... norepinephrine, serotonin, and dopamine, are regulated a finding ... drugs for depression target the regulatory process for neurotransmitters, ... to work in other cases. Recent findings ... the brain, are key players in the management of ...
... ... informed on Swine Flu developments are part of the awareness strategy , ... Edmonton, AB (Vocus) October 18, ... up to date on all developments, says a school representative. , ,“We post the ...
... e cigarettes sales have generally been tobacco smoking individuals ... online sales associate for E-Cigarettes National, reports an influx ... loved ones that smoke. "Some of these callers are ... starter kit for their spouses or partners that have ...
... more likely the pain, says research led by an 11-year-old, , ... for more than an hour a day increase their chances of ... The lead author of the study knows this all too well. ... joint pain among his classmates at Rossman Elementary in St. Louis, ...
... more likely to die within a year of major ... -- Veterans with post-traumatic stress disorder face an increased ... is performed years after they have completed their service, ... on 1,792 male veterans who had major non-cardiac, non-emergency ...
Cached Medicine News:Health News:Metals could forge new cancer drug 2Health News:Reeves College Prepares Campuses for H1N1 Virus 2Health News:Online Sales of E Cigarettes Expected to Rise Over the Holidays 2Health News:Video Games Can Play Havoc With Kids' Joints 2Health News:Video Games Can Play Havoc With Kids' Joints 3Health News:Post-Traumatic Stress May Raise Death Risks 2
Features soft, low friction sheath that extends beyond the tip....
Facilitates intubation of tracheal tubes....
SunGlide™ Stylette - Green Adult. Use in 7.0 to 10mm tubes. 25/box....
Fiber Optic Stylette with Adjustable Stop 18., ,Fiber optic handles require two AA batteries not included....
Medicine Products: